• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
LGP 0.00% 81.0¢

LITTLE GREEN PHARMA LTD - Corporate Spotlight

News: Little Green Pharma (ASX:LGP) breaks new ground and acquires Denmark facility via... News: Little Green Pharma (ASX:LGP) breaks new ground and acquires Denmark facility via $15m investment from mining mogul Gina Rinehart. LGP is an Australia-based medicinal cannabis company with a track record of sales growth with a clear pathway to increasing margins and driving revenues.More

Corporate Spotlight

News: Little Green Pharma (ASX:LGP) breaks new ground and acquires Denmark facility via $15m investment from mining mogul Gina Rinehart. LGP is an Australia-based medicinal cannabis company with a track record of sales growth with a clear pathway to increasing margins and driving revenues
View the full Corporate Spotlight arrow Created with Sketch.

LGP continues EUR expansion w/ Denmark acquisition

LGP ENTERS EU WITH BIG END BACKING

arrow-down-2 Created with Sketch.

Little Green Pharma (ASX:LGP) enters EU with big end of town backing

Sponsored, The Market Herald Thematica

ASX:LGP
21 July 2021 18:23 (AEST)
Little Green Pharma (ASX:LGP) - Managing Director Fleta Solomon. - The Market Herald
Managing Director Fleta Solomon.
Source: Little Green Pharma.

  • Little Green Pharma (LGP) recently announced it is acquiring a Danish cannabis company with the help of Gina Rinehart's Hancock Prospecting
  • It's a significant move for the ASX-lister, as it gives the company the backing of a the big end of town - the Australia's resources sector
  • LGP says the $15 million funding injection will help the business expand its cultivation capabilities and growth strategy
  • The company also says the backing opens the door to further resource investment in the cannabis sector and brings more legitimacy to the treatment

Little Green Pharma's (LGP) decision to buy a Danish cannabis business was significant for a number of reasons.


However its most significant impact was bringing the big end of town - the Australian resources sector - into the cannabis space.


Billionaire Gina Rinehart's Hancock Prospecting invested $15 million in the company in support of the Denmark deal, opening the door to other potential resources-backed investments.


LGP said the investment was encouraging as it brought attention not just to its own operations, but also the broader medicinal cannabis sector in Australia.


The cannabis company at the heart of the deal


Founded back in 2016, LGP describes itself as a first-mover in the cannabis market.


This is because LGP was the first Australian cannabis company to produce locally-grown medical-grade cannabis products, as well as the first Australian medicinal cannabis producer to export products from Australia.


Since those milestones, the company has expanded its cannabis cultivation facility in WA's South West, where it has historically grown and produced its cannabis-based flower and oil medicines.


These medicines can be accessed via the Special Access Scheme, an Australian Government program that controls the access of certain therapeutic goods.


Meanwhile, along with being the first local producer and exporter, LGP last year became the first cannabis company to team up with a health insurer to make its treatments more affordable.


LGP's Fleta Solomon said the company had spent the past few years working to improve Australian patients' access to cannabis medicines.


"Little Green Pharma has always had Australian patient access at the forefront of everything we do," Ms Solomon said.


"We are proud of our partnership with national private health insurer, Health Insurance Fund of Australia (HIF), to further support improved access to and affordability of medicinal cannabis products through the payment of a rebate to eligible HIF members."


continues.....


Read the Full Article on The Market Herald here

LGP FLAGS ACQUISITION AND CAPITAL RAISE

arrow-down-2 Created with Sketch.

Little Green Pharma (ASX:LGP) flags acquisition and capital raise

ASX:LGP
Little Green Pharma (ASX:LGP) - Managing Director, Fleta Solomon - The Market Herald
Managing Director, Fleta Solomon
Source: Little Green Pharma

  • Little Green Pharma (LGP) has entered a trading halt ahead of a proposed acquisition and capital raise announcement
  • The cannabis company hasn't announced any details about the raise or purchase, with full details expected to be announced by Wednesday
  • The last time LGP raised capital was in March this year, with a share placement plan generating an extra $5 million in cash for the company to spend
  • Meanwhile, before Monday's trading halt, LGP announced it had signed a distribution partner to sell its products in Poland

Little Green Pharma (LGP) has entered a trading halt ahead of a proposed acquisition and capital raise announcement.


The cannabis stock halted its shares from trading before market opened on Monday, June 21, with the halt expected to end on Wednesday, June 23.


LGP shareholders will have to wait until then to find out the full details of the acquisition, as well as how much the company is planning to raise.


This is the second time in recent months Little Green Pharma has carried out a fundraise.


The business raised capital in March this year, with a share placement plan generating an extra $5 million in cash for the company to spend.


Meanwhile, before Monday's trading halt, LGP had been busy announcing an exclusive Polish distribution partner.


The company revealed last week it was teaming up with Medezin Sp., a subsidiary of Pelion SA, to sell its medicinal cannabis products in the region.


Under the deal, Medezin will aim to capture 20 per cent of the Polish medicinal cannabis oil market and at least 10 per cent of the Polish high-THC medicinal cannabis flower market using LGP's products.


Read the Full Article on The Market Herald here

LGP ACQUIRES DENMARK FACILITY

arrow-down-2 Created with Sketch.

Little Green Pharma (ASX:LGP) acquires Denmark facility via Gina Rinehart investment support

Health Care

ASX:LGP
Little Green Pharma (ASX:LGP) - Managing Director, Fleta Solomon - The Market Herald
Managing Director, Fleta Solomon
Source: Little Green Pharma

  • Little Green Pharma (LGP) is planning to acquire a Denmark (WA) cannabis facility after raising $27.2 million in funding via a share placement
  • The ASX-listed cannabis stock says $15 million of that figure will come from Hancock Prospecting, which is owned by Australian billionaire Gina Rinehart
  • Once the placement is finalised, Hancock Prospecting will hold a 10 per cent stake in LGP, which plans to issue 45.3 million shares at 60 cents each
  • The company will use the funds from the placement to pay for the C$20 million (A$21.47 million) Denmark business

Little Green Pharma (LGP) is planning to acquire a Denmark cannabis facility in southwestern Western Australia after successfully raising $27.2 million in funding via a share placement.


The ASX-listed cannabis stock came out of a trading halt on Tuesday to announce the capital raise and acquisition news.


LGP said it had received firm commitments to raise $27.2 million with $15 million of that figure to come from Hancock Prospecting, which is owned by Australian billionaire Gina Rinehart.


Under the share placement, Little Green Pharma is set to issue 45.3 million LGP shares at 60 cents each, with Rinehart's business set to walk away with a 10 per cent stake in the cannabis company.


Hancock Prospecting’s General Manager of Business Development Dan Wade said: "In supporting LGP's investment in its new facility and becoming a substantial shareholder, we hope to help many thousands of Australian and overseas patients access much-needed cannabis medicines.


"We believe medicinal cannabis has a vital role in helping to treat a range of chronic conditions, and we’re pleased to support an Australian medicinal cannabis company in LGP that continues to put patients first and contribute to the development of this helpful and emerging industry."


LGP will use the funds for the placement to pay leading Canadian cannabis stock Canopy Growth Corporation C$20 million (A$21.47 million) for a Denmark cannabis business.


LGP said the facility near the town in southwestern WA was fully operational and had capacity to produce in excess of 20 tonnes of biomass per annum, including 12 tonnes per annum of dried cannabis flower.


LGP Managing Director Fleta Solomon said the acquisition was a step change for the company.


"We have been speaking for some time about the need to increase our production capacity and the Denmark facility not only gives us the cultivation and manufacturing capacity we need, but does so immediately," she said.


"We won’t be constrained by the two-year build and permitting time required to expand our existing West Australian facility."


LGP expects the shares issued under this recent share placement to settle by June 28.


Read the Full Article on The Market Herald here

LGP RECEIVES $2.5M PURCHASE ORDER

arrow-down-2 Created with Sketch.

Little Green Pharma (ASX:LGP) receives $2.5M purchase order from DEMECAN

Health Care

ASX:LGP
Little Green Pharma (ASX:LGP) - Managing Director, Fleta Solomon - The Market Herald
Managing Director, Fleta Solomon
Source: Little Green Pharma

  • Little Green Pharma (LGP) has received a $2.5 million purchase order from DEMECAN for 21,300 units of its medicinal cannabis flower medicine
  • This is the fourth order DEMECAN has placed, following 500, 9000 and 17,000 units for delivery in CYQ1, CYQ2 and CYQ3, respectively
  • This new order brings DEMECAN's total orders to 47,800 units for a total cost of $5.7 million in CY21 alone
  • To capitalise on the growing demand, Little Green Pharma has brought its existing cultivation facilities to full capacity

Little Green Pharma (LGP) has received a $2.5 million purchase order from DEMECAN for 21,300 units of its medicinal cannabis flower medicine.


Based in Germany, DEMECAN is a pharmaceutical wholesaler that covers all the manufacturing steps from cultivation, processing, storage and delivery.


This is the fourth order DEMECAN has placed, following 500, 9000 and 17,000 units for delivery in CYQ1, CYQ2 and CYQ3, respectively.


This new order brings DEMECAN's total orders to 47,800 units for a total cost of $5.7 million in CY21 alone.


To capitalise on the growing demand, Little Green Pharma has brought its existing cultivation facilities to full capacity.


Managing Director Fleta Solomon commented: "This order means a lot more than just the value of the sales it represents, it's tangible evidence of the success of our strategy."


"We are currently in a position where all flower product we produce is sold into Australia and overseas markets and we have customers looking for more.


"It heightens the urgency for us to focus on increasing our production capacity to capitalise on the brand equity we have built in the market."


Read the Full Article on The Market Herald here

LGP PURCHASES NEW LAND & RECEIVES ORDER

arrow-down-2 Created with Sketch.

Little Green Pharma (ASX:LGP) purchases new land and receives DEMECAN order

Health Care

ASX:LGP    
Little Green Pharma (ASX:LGP) - Managing Director, Fleta Solomon - The Market Herald
Managing Director, Fleta Solomon

  • Medicinal cannabis manufacture Little Green Pharma (LGP) has received a firm purchase order and acquired new land for expansion
  • The company agreed to purchase two properties near its cultivation and manufacturing facilities in South West Western Australia
  • Under the agreement, LGP will purchase the properties for between $5.5 million and $7.5 million in a mixed cash-and-scrip deal
  • LGP is planning to expand its current capacity by the second half of this year
  • Additionally, the company has received a firm purchase order from German pharmaceutical wholesaler Deutsche Medizinalcannabis (DEMECAN)
  • On the market today, LGP is down 1.43 per cent and is trading at 69 cents per share


Medicinal cannabis manufacture Little Green Pharma (LGP) has received a firm purchase order and acquired new land for expansion. 


New land

The medicinal cannabis manufacture has agreed to purchase two properties near its cultivation and manufacturing facilities in southwest Western Australia.


Under the agreement, LGP will purchase the land in cash and script payment of between $5.5 million and $7.5 million. The new land covers around 16,000 square metres. 


LGP says the new purchase will help service the higher-than-expected international and domestic market demand for LGP cannabis flower medicines.


Through the acquisition, the company can double its indoor cultivation capacity by 3000 square metres within its existing high-security fencing line. 


LGP expects to complete the expansion in the second half of this year.


Purchase order 

Alongside news of the expansion, the company has received a firm purchase order from German pharmaceutical wholesaler Deutsche Medizinalcannabis (DEMECAN). 


The DEMECAN purchase order includes 9000 units of cannabis flower medicines to be delivered in the second quarter of the current 2021 year.


This follows the first commercial shipment of cannabis follower to Germany in February


The companies have a medicinal cannabis purchase agreement, through which LGP can sell and export up to 1000 kilograms of its dried cannabis flower to DEMECAN each year.


On the market today, LGP is down 1.43 per cent and is trading at 69 cents per share at 12:56 pm AEDT.



Read the full article The Market Herald here.

LGP DELIVERS FIRST FRENCH SHIPMENT

arrow-down-2 Created with Sketch.

Little Green Pharma (ASX:LGP) delivers first French shipment

Health Care

ASX:LGP  
Australian first: Little Green Pharma (ASX: LGP) sends medicinal cannabis oils to Germany
Source: Little Green Pharma

  • Little Green Pharma (LGP) has delivered its first shipment of medicinal cannabis oil to France, ahead of the upcoming national trial 
  • Earlier this year, LGP won a government tender to be the primary supplier of medicinal cannabis oils for a national trial in France
  • The two-year trial will test the efficacy, safety and quality of medicinal cannabis in up to 3000 patients
  • Notably, if this trial is successful it may lead to the legalisation of medicinal cannabis in France
  • The cannabis oils are expected to be made available to trial patients later this month
  • On the market this afternoon, LGP is up 2.34 per cent and is trading at 65.5 cents per share

Little Green Pharma (LGP) has delivered its first shipment of medicinal cannabis oil to France. 


The products have been shipped for the French national medicinal cannabis trial.


In January, LGP won a government tender to be the primary supplier of medicinal cannabis oils for a national trial in France. The two-year trial will test the efficacy, safety and quality of medicinal cannabis in up to 3000 patients. 


Notably, if this trial is successful it may lead to the legalisation of medicinal cannabis in France. 


The cannabis oils are expected to be made available to trial patients later this month. 


Being the primary supplier of this trial, LGP is following its strategy of growing and holding significant market share in key European growth markets, including Germany, the U.K. and France. 


Additionally, earlier this week, the company completed its $5 million share purchase plan to help speed up sales and marketing efforts in both Australia and overseas. 


On the market this afternoon, LGP is up 2.34 per cent and is trading at 65.5 cents per share at 12:44 pm AEDT.


Read the full article on The Market Herald here.

LGP TABLES 427% REVENUE INCREASE

arrow-down-2 Created with Sketch.

Little Green Pharma (ASX:LGP) tables 427pc revenue increase

Health Care

ASX:LGP    
Little Green Pharma (ASX:LGP) - Managing Director, Fleta Solomon - The Market Herald
Managing Director, Fleta Solomon

  • Medicinal cannabis manufacturer Little Green Pharma (LGP) has tabled a 427 per cent increase in revenue in its half-year report
  • The healthcare stock ended December with $3.77 million in revenue, up from just $716,000 in revenue at the end of 1H FY20
  • An additional 150 GPs signed up with Little Green over the period, while 4900 new patients subscribed to its products
  • LGP's sales also grew substantially year on year, with over 21,000 units sold, representing an increase of 340 per cent 
  • Little Green ended the half-year with a maiden profit, a strong turnaround from the previous year's $5.5 million loss
  • It also had $4.45 million in the bank and has since raised an additional $22.1 million in capital via a placement
  • Company shares are trading for 71 cents, up 2.9 per cent

Medicinal cannabis manufacturer Little Green Pharma (LGP) has tabled a 427 per cent increase in revenue in its half-year report.


LGP ended December with a total of $3.77 million in revenue, well up on the $716,000 in revenue it reported at the end of the first half of the 2020 financial year.


The healthcare stock is crediting the stellar increase in revenue to a rise in both sales and customers.


An additional 150 GPs signed up to be able to subscribe to Little Green's cannabis oils over the period, while another 4900 new patients accessed its products.


This represents a 250 per cent increase compared to the previous corresponding half and brings the company's total lifetime patients to around 9500.


Sales also grew substantially year on year, with over 21,000 units sold during 1H FY21 — representing an increase of 340 per cent.


Little Green ended the period with its first half-year profit of just over $484,000, a strong turnaround considering it ended the previous corresponding period with a $5.5 million loss.


The company also had around $4.45 million in the bank and, since the end of December, has raised an additional $22.1 million in capital via a placement to investors.


In addition to this, LGP is offering shareholders a chance to top-up their investment by opening a $5 million share purchase plan.

Meanwhile, since the end of 1H FY21, the company has begun shipping cannabis flowers to Germany and also released a new oil formulation.


Company shares have jumped up slightly following today's half-year release, trading at 71 cents, up 2.9 per cent at 2:23 pm AEDT.


Read the full article on The Market Herald here.

LGP OPENS $5M SPP

arrow-down-2 Created with Sketch.

Little Green Pharma (ASX:LGP) opens $5M SPP

Health Care

ASX:LGP   
Little Green Pharma (ASX:LGP) - Managing Director, Fleta Solomon - The Market Herald
Managing Director, Fleta Solomon

  • Little Green Pharma (LGP) has opened its share purchase plan (SPP) with aims to raise up to $5 million
  • Under the plan, eligible shareholders will be able to subscribe for up to $30,000 worth of shares, which are priced at 65 cents 
  • This price represents a 17.3 per cent discount to the five-day volume-weighted average price 
  • LGP will use the money to speed-up sales and marketing efforts in both Australia and overseas as well as expand its manufacturing capacity 



Little Green Pharma (LGP) has opened its share purchase plan (SPP) with aims to raise up to $5 million.


This follows on from a recently announced placement to sophisticated, experienced and professional investors to raise $22 million. 


All up, around 34 million shares were issued to participants at 65 cents. 


Under the SPP, eligible shareholders will be able to subscribe for up to $30,000 worth of shares, which are also priced at 65 cents. 

This price represents a 17.3 per cent discount to the five-day volume-weighted average price.


The company's Australian-based Directors, Angus Caithness and Neale Fong, intend to apply for the maximum $30,000 worth. 

In the event of oversubscriptions, LGP has the right to scale-back applications. 


LGP will use the money from both the placement and share purchase plan to speed-up sales and marketing efforts in both Australian and overseas markets, and expand its manufacturing and cultivation capacity. 


The plan is set to close on March 3 and shares will be issued on March 11 and begin trading on the ASX on March 12. 


Read the full article on The Market Herald here.

LGP GEARS UP FOR A CAPITAL RAISE

arrow-down-2 Created with Sketch.

Little Green Pharma (ASX:LGP) gears up for capital raise, commercial update

The Market Herald Deal Room

ASX:LGP    
Little Green Pharma (ASX:LGP) - COO, Paul Long (left) & HIF CEO, Justin James (right) - The Market Herald
COO, Paul Long (left) & HIF CEO, Justin James (right)

  • Little Green Pharma (LGP) has placed its shares in a trading halt ahead of an upcoming capital raise and material commercial announcement
  • Further details on these activities are expected on or before February 9, when normal trading is set to resume
  • The announcement comes less than a week after the company released its quarterly activities report
  • In the update, LGP detailed its expansion activities into European markets and flagged plans for a partnership with the Health Insurance Fund

Little Green Pharma (LGP) has placed its shares in a trading halt ahead of an upcoming capital raise and material commercial announcement.


The trading halt is expected to remain until a formal disclosure is made to the market regarding the raise and commercial announcement on or before Tuesday, February 9.


At this stage, the medicinal cannabis player has not indicated how much it is seeking to raise or what the proceeds will go towards. 


The announcement comes less than a week after the company released its quarterly activities report for the December quarter.

Over this period, LGP continued its international market pursuits, completing its fist export to Germany and receiving a primary supplier role for a national French medicinal cannabis trial.


The company also flagged plans to work with the Health Insurance Fund (HIF) to support improved access and affordability of medicinal cannabis through rebates to eligible HIF members.


In terms of finances, cash receipts for the period came in at $1.86 million, taking LGP's cash position for the quarter to just shy of $4.5 million.



Read the full article on The Market Herald here.

LGP SET TO RAISE $22M FOR GROWTH

arrow-down-2 Created with Sketch.

Little Green Pharma (ASX:LGP) set to raise $22M for growth

Health Care

ASX:LGP 
Little Green Pharma (ASX:LGP) - Managing Director, Fleta Solomon - The Market Herald
Managing Director, Fleta Solomon

  • Little Green Pharma (LGP) has received firm commitments to undertake a $22 million placement
  • All up, 34 million new fully-paid ordinary shares will be issued to investors at 65 cents
  • This price represents a 30.5 per cent discount on LGP's trading price of 93.5 cents on February 4
  • LGP is also planning to undertake a share purchase plan to raise up to $5 million
  • Eligible shareholders will be able to subscribe for up to $30,000 worth of shares without incurring any brokerage or transmission costs 
  • LGP will use the money to speed-up sales and marking efforts in both Australia and overseas, and expand its manufacturing and cultivation capacity

Little Green Pharma (LGP) has received firm commitments to undertake a $22 million placement. 


The medical cannabis company entered a trading halt on February 5 but did not disclose how much it would be raising or what the funds would be used for. 


All up, 34 million new fully-paid ordinary shares will be issued to investors at 65 cents. 


This price represents a 30.5 per cent discount to LGP's trading price of 93.5 cents on February 4, and an 8.4 per cent discount to the 20-day volume-weighted average price. 


Shares are expected to settle on or around February 15. 


LGP is also planning to undertake a share purchase plan to raise up to $5 million. 


Eligible shareholders will be able to subscribe for up to $30,000 worth of shares, which will be priced the same as the placement of 65 cents. 


The plan will open on February 15 and close on March 3. Shares will be allocated on March 11 and begin trading on the ASX on March 12. 


LGP will use the money from both the placement and share purchase plan to speed-up sales and marking efforts in both Australian and overseas markets, and expand its manufacturing and cultivation capacity. 


"Little Green Pharma has gone from strength to strength, and has achieved immense growth in the last year, most recently setting new records to quarterly revenue, unit sales, and patient numbers," Managing Director Fleta Solomon said. 


"We expect the next 12 months to be very exciting for the company and look forward to reporting on our continued success," she added.



Read the full article on The Market Herald here.

LGP ENDS 2020 ON A HIGH

arrow-down-2 Created with Sketch.

Little Green Pharma (ASX:LGP) ends 2020 on a high

Health Care

ASX:LGP   
Australian first: Little Green Pharma (ASX: LGP) sends medicinal cannabis oils to Germany
Source: Little Green Pharma




  • Medicinal cannabis company Little Green Pharma (LGP) has updated the market on its financial and operational activities over 2020's final quarter
  • In terms of finances, LGP's quarterly sales revenue hit $2.45 million, marking a 90 per cent upswing on the previous quarter
  • All up, cash receipts for the period came in at $1.86 million, taking LGP's cash position for the quarter to just shy of $4.5 million
  • The ASX-lister also continued its international market pursuits, completing its fist export to Germany and receiving a primary supplier role for a national French medicinal cannabis trial

Medicinal cannabis company Little Green Pharma (LGP) has updated the market on its financial and operational activities over 2020's final quarter.


Financial highlights 

In terms of finances, LGP posted a record unaudited quarterly sales revenue of $2.45 million, representing a 90 per cent upswing on the previous quarter. 


Unit sales also saw an increase over the period, totalling more than 12,500 in Australia, marking a 50 per cent increase on the quarter before. 


Notable expenditure for the ASX-lister includes $299,000 on research and development, which went towards the development of new products, new delivery systems and payments to research partners. 


All up, cash receipts for the period came in at $1.86 million, taking LGP's cash position for the quarter to just shy of $4.5 million.


Operational highlights 

November 2020 saw Little Green Pharma's first commercial shipment of medicinal cannabis oils to Germany. 


It looks to mark the first of many international pursuits for the company, with its first shipment of cannabis flower medicines set for the E.U. market early in the next quarter.


The company has also been awarded a primary supplier role for a national French medicinal cannabis trial alongside a prominent French pharmaceutical distributor. 


The move is hoped to secure the company a solid position in the French cannabis market if and when cannabis becomes legal in the country. 


In further partnership developments, LGP also announced it would be working with the Health Insurance Fund in a bid to support improved access and affordability of medicinal cannabis through rebates to eligible HIF members. 


The company says over 60 patients have been successfully onboarded as part of its soft launch, with a formal rollout anticipated early in the next quarter.


Read the full article on The Market Herald here.

LGP WINS TENDER TO SUPPLY FRANCE

arrow-down-2 Created with Sketch.

Little Green Pharma (ASX:LGP) wins tender to supply medicinal cannabis for national French trial

Health Care

ASX:LGP   
Little Green Pharma (ASX:LGP) wins tender to supply medicinal cannabis for national French trial


  • Little Green Pharma (LGP) has won a government tender to be a primary supplier of medicinal cannabis oils for a national trial in France
  • The two-year trial will test the efficacy, safety and quality of medicinal cannabis products in up to 3000 patients
  • As part of the trial, LGP will partner with leading pharmaceutical distributor, Intsel Chimos, who will undertake batch-release, distribution, medical information and drug safety obligations
  • Little Green Pharma will be responsible for manufacturing and supplying its medicines into France at its own cost
  • Ultimately, if the trial is successful, it may lead to the legalisation of medicinal cannabis in France — providing LGP with a "first-mover advantage"



Little Green Pharma (LGP) has been selected as a primary supplier of medicinal cannabis oils for a national trial in France.


Since 2018, the French National Agency for the Safety of Medicines and Health Products has been developing the tender for this two-year trial. The trial is aimed at testing the efficacy, safety and quality of medicinal cannabis products in up to 3000 patients.


These patients will have varying conditions such as refractory neuropathic pain, drug-resistant epilepsy, intractable symptoms linked to cancer or anticancer treatment, palliative situations, or painful spasticity from multiple sclerosis or other issues within the central nervous system.


Ultimately, if the trial is successful, it may lead to the legalisation of medicinal cannabis in France.


The medicinal cannabis trial is in partnership with Intsel Chimos, a leading pharmaceutical distributor and recognised hospital partner in France. 


Since 1966, the French company has specialised in importing and distributing medicines to hospitals and dispensaries across France. 


Intsel Chimos' role within the partnership involves undertaking batch-release, distribution, medical information and drug safety obligations. Meanwhile, LGP will be responsible for manufacturing and supplying its medicines into France at its own cost.


"We are very proud of our partnership's success in the French national tender and see this tender win as strong evidence of LGP successfully implementing its export-led global sales strategy and demonstrating the benefits of Australian Good Manufacture Practices (GMP) quality manufacturing in global pharmaceutical markets," Little Green Pharma Managing Director Fleta Solomon said.


Fleta also congratulated Intsel Chimos for developing a competitive bid for the tender and is looking forward to working together.


"We trust this marks the beginning of a long and rewarding partnership as we look to grow and cement our reputation amongst French patients and prescribers as a world-class medicinal cannabis supplier," she said.


Significantly, this tender provides Little Green Pharma with a "first-mover advantage" in case medicinal cannabis does end up being legalised in France after the trial.


Read the full article on The Market Herald here.

LGP WELCOMES TGA DECISION CANNABIDIOLS

arrow-down-2 Created with Sketch.


Little Green Pharma (ASX:LGP) welcomes TGA decision on cannabidiols

Health Care

ASX:LGP   
Australian first: Little Green Pharma (ASX: LGP) sends medicinal cannabis oils to Germany

Source: LGP

  • Medicinal cannabis company Little Green Pharma (LGP) has welcomed the Therapeutic Goods Administration's (TGA) regulatory changes to cannabidiol (CBD)
  • The TGA has down-scheduled some CBD products and also increased the daily maximum dosage limit 
  • This decision means from early next year registered CBD products can be dispensed over-the-counter without the need for a prescription
  • LGP has congratulated the TGA for the change, stating the down-scheduling will make medicinal cannabis more widely available across Australia
  • Shares in Little Green Pharma have ended the day down a slight 0.83 per cent trading at 59.5 cents each

Little Green Pharma (LGP) has welcomed the Therapeutic Goods Administration's (TGA) wide-ranging changes to cannabidiol (CBD) regulation.


The medicinal cannabis business has joined other ASX-listed companies in congratulating the TGA for making changes to the rules around dispensing CBD.


The regulatory body has down-scheduled some CBD products to pharmacist-only medications and increased the daily maximum dosage limit to 150 mg per day.


It's an important change, as the down-scheduling means from early next year registered CBD products can be dispensed over-the-counter without the need for a prescription.


Commenting on the TGA’s decision, Little Green Pharma Managing Director Fleta Solomon said the change should benefit the entire industry.


"This final scheduling decision demonstrates both the TGA’s commitment to patient safety and product quality as well as its appreciation of prescriber and patient needs," Fleta said.


"We wish to congratulate the TGA on its decision and look forward to the significant benefits it will bring to both Australian patients and prescribers and the Australian medicinal cannabis industry as a whole."


As well as congratulating the TGA for its decision, Little Green has also flagged plans to potentially register one or two of its cannabis oil medicines.


The company said the TGA's planned increase of the maximum daily dose will give it more confidence to progress down the path of Australian Register of Therapeutic Goods (ARTG) CBD medicine registrations.



Read the full article on The Market Herald here.

AUSTRALIA FIRST: LGP SHIPS TO GERMANY

arrow-down-2 Created with Sketch.


Australian first: Little Green Pharma (ASX: LGP) sends medicinal cannabis oils to Germany

Health Care

ASX:LGP    

Australian first: Little Green Pharma (ASX: LGP) sends medicinal cannabis oils to Germany

Source: LGP

  • Little Green Pharma (LGP) has become the first Australian company to send medicinal cannabis oils to Germany
  • The company has exported 2400 oils, valued at $600,000, to German pharmaceutical importer CC Pharma
  • The shipment is expected to clear German customs next week, then the oils will complete a batch testing before being sold in the country 
  • Germany is the third-largest medicinal cannabis market globally — behind the U.S. and Canada — and is the largest market in Europe.
  • On the market this afternoon, Little Green is up 8.57 per cent and trading for 38 cents per share

Little Green Pharma (LGP) is the first company to export Australian medicinal cannabis oils to Germany. 


The company has sent an initial 2400 units, valued at $600,000, of its cannabis oils to German pharmaceutical importer CC Pharma. The shipment is expected to clear customs next week. 


Once they arrive, the oils will be batch-tested and released for sale on the German market. 


Germany is the third-largest medicinal cannabis market globally — behind the U.S. and Canada — and is the largest market in Europe. 

Managing Director Fleta Solomon is pleased to supply CC Pharma with the medicinal cannabis oils. 


"The demand for Little Green products signifies not only a vote of confidence in the company, but also in the ability of Australia’s homegrown medicinal cannabis industry to compete with major international medicinal cannabis companies to supply the German market," she said. 


"With our expanded cultivation and manufacturing facility, Little Green is well placed to ensure consistent supply to both Australia and offshore markets in the future," she added. 


Earlier this month, the company entered a strategic partnership with private health insurer HIF. Under the deal, HIF will issue a $105 rebate per script to eligible members for medicinal cannabis products. 


On the market this afternoon, Little Green is up 8.57 per cent and trading for 38 cents per share at 12:14 pm AEDT.



Read the full article on The Market Herald here.

LGP THE FUTURE OF MEDICINAL CANNABIS

arrow-down-2 Created with Sketch.

Little Green Pharma (LGP)’s recent partnership with health insurer HIF shows how medicinal cannabis treatments could shake-up the lucrative pharmaceutical market in Australia and beyond.


Under the deal, HIF will offer a rebate of up to $105 per bottle of LGP's cannabis oils, substantially reducing the products’ recommended retail price. Crucially, by making medicinal cannabis more affordable, LGP and HIF have opened the door for the treatment's wider use.


They've also placed the drug in direct competition with comparable prescription and over-the-counter medications, not to mention patients currently treating themselves with cannabis sourced from the black market.


The market as a whole

There's no doubt about it — the pharmaceutical industry is big business.


The global pharma market was assigned an estimated worth of US$1.25 trillion (around A$1.72 trillion) in 2019, having tripled in worth in the last 18 years.


In Australia, the pharmaceutical market is much smaller in comparison but still manages to have an estimated worth of over $25 billion in 2020.


The Federal Government has already declared it spent $12.7 billion subsiding prescription medication last year as part of its Pharmaceutical Benefits Scheme (PBS), which subsidises the cost of common prescriptions.


Looking at ASX-listed businesses, leading drugmaker CSL (CSL) recorded US$8.8 billion (around A$12.1 billion) in sales revenue for the 2020 financial year, as well as US$2.1 billion (approximately A$2.9 billion) in profit after tax.


The ongoing value of the pharma markets also coincides with the growing demand for both prescription and over-the-counter drugs.

A recent survey found nine million Aussies currently take a prescribed medicine every day, while eight million take two or more prescribed medicines each week. It also estimated two million people take over-the-counter medicine daily and more than seven million take a complementary medicine daily.


Given the demand and market size of the medicines industry, Little Green Pharma's partnership with a health insurer shows cannabis is a legitimate competitor in the business of treating chronic and acute ailments.




Little Green Pharma explained

So what exactly is Little Green Pharma, and how is it different to other cannabis companies?


LGP first began as a privately owned company back in 2016 and has grown to become one of a handful of vertically integrated cannabis business listed on the ASX.


This means it both cultivates, produces, manufactures and wholesales its cannabis products, with both the cultivation and manufacturing plants located onsite together in WA's southwest.


The company is fully licenced by Australian authorities, recently receiving a Good Manufacturing Practices (GMP) licence from the Therapeutic Goods Administration (TGA) for its new manufacturing facility.


Its cultivation plant was also expanded over the last year and now comprises nine flowering rooms, two mother plant rooms, and two vegetation rooms.


Altogether, that's enough product to manufacture over 110,000 bottles of medicinal cannabis oil per annum: Little Green Pharma's main product. 


The company produces four different cannabis oil which contain different formulations of both CBD and THC — the two main components of cannabis prescribed for pain, inflammation, nausea, spasticity and seizures.




Source: LGP Prospectus

Accessing LGP's oils


Currently, Australian patients are able to access Little Green Pharma's range of cannabis oils via three different pathways, including the Special Access Scheme Category B (SAS-B) — where healthcare practitioners, including GPs, can obtain approval to prescribe medicinal cannabis to individual patients.


The other two options are the Authorised Prescriber Scheme —where authorised doctors can prescribe specific medicinal cannabis products for any patient diagnosed with a specific condition — and clinical audits and trials.


These are the main options available not only for Little Green Pharma, but for other cannabis producers as well. While cannabis is legal, it's still not available as a registered prescription medicine for the substantial majority of conditions.

Despite the barriers to accessing the product, more than 6700 patients have accessed LGP's range of medicinal cannabis oils as of September 2020.



Enter HIF

However, with the backing of a major insurance fund, Little Green Pharma's range of products will become more affordable for Australians to access going forward.


LGP Chief Operating Officer Paul Long has described the deal as a "milestone" which will open the door for medicinal cannabis as a treatment going forward.


"This partnership is hopefully one of many, but it really acknowledges the fact that medicinal cannabis is becoming mainstream for clinical practitioners and for patients across Australia," he said.


HIF CEO Justin James agreed and said cannabis was too often overlooked as a treatment option for many Australians.

"What is clear to us in feedback is that patients are keen to see alternatives to standard prescription medicines," he explained.

"Medicinal cannabis is becoming far more widely accepted and we know that it has multiple benefits, and can treat multiple life-stage illnesses" he added.


Looking ahead, Little Green Pharma believes its partnership with HIF will be the first of many as the healthcare industry wakes up to the benefits and possibilities of medicinal cannabis treatments.



Read the full article here on The Market Herald. 


LGP PARTNERS WITH HIF

arrow-down-2 Created with Sketch.


Little Green Pharma (ASX:LGP) partners with HIF

Health Care

ASX:LGP    


Little Green Pharma COO - Paul Long 

HIF CEO - Justin James



  • Medicinal cannabis company Little Green Pharma (LGP) has entered a strategic partnership with private health insurer HIF
  • Under the deal, HIF will issue a $105 rebate per script to eligible members for medicinal cannabis products
  • Additionally, the partnership will support future research into medical cannabis, as HIF members will have priority participation in the research
  • HIF is the first major Australian health fund to publicly support medicinal cannabis treatments


Little Green Pharma (LGP) has entered a strategic partnership with private health insurer HIF. 


Under the deal, HIF will issue a rebate to eligible HIF members for medicinal cannabis products. The deal aims to improve access to and the affordability of medicinal cannabis. 


Additionally, the partnership will support future research on the role medical cannabis can play in improving quality of life, as certain HIF members are entitled to priority participation.


This contract represents the first time a major Australian health fund has publicly backed medicinal cannabis treatments and its usefulness for Australians who are suffering from numerous health conditions. 


Little Green Pharma is a West Australian business that creates its own medicinal cannabis oils. 


Under the rebate, HIF members will receive up to $105 back per eligible medicinal cannabis script. The partnership is set to last between 18 months and two years, depending on the length of the study.

 

Little Green Pharma Managing Director Fleta Solomon said the partnership is exciting for both parties. 


"Our company has always had Australian patient access at the forefront. We were the first company in Australia to launch with locally-grown and affordable medicinal cannabis products," she said. 


"Our disruptive pricing strategy led to the cost of medicinal cannabis products being significantly reduced in price nationally. We are proud to further contribute to driving improved affordability and our partnership with HIF, another patient-focused company, will mean better access to medicinal cannabis products for patients across Australia," she added. 


HIF CEO Justin James said partnering with Little Green Pharma was in line with the company's goal to provide new, alternative treatment choices to its members. 


"We are exceptionally pleased to be the first Australian health fund to publicly declare our support for medicinal cannabis treatments and provide our members with rebates on these products," he said. 


"As a member-based health fund, our community is the motivation for everything we do, so assisting members through treatment options that can dramatically improve quality of life across different life stages is a key focus," he concluded. 



Read the full article on The Market Herald here. 

ABOUT US

arrow-down-2 Created with Sketch.


First in Australia


Little Green Pharma was the first medicinal cannabis company in Australia to produce locally-cultivated medicinal-grade cannabis oil products.


We are a responsive organisation that has a proven ability to quickly adapt and succeed in a dynamic, fast-moving market environment. 


Producing Cannabis Oil in Australia since 2018


Established in 2016 as a privately-owned company in Perth, Western Australia, we have been supplying Australian patients with naturally grown medicinal cannabis products since August 2018. Little Green Pharma’s growth strategy is initially focused on continued expansion in Australia, followed by expansion into European and other international markets.




Stringent quality growing and manufacturing standards


We cultivate our medicinal cannabis plants in accordance with stringent Australian quality standards in the South West of Western Australia and manufacture our products in a Good Manufacturing Practices (GMP) certified facility in Perth.




VIDEOS

arrow-down-2 Created with Sketch.

LGP continues EUR expansion w/ Denmark acquisition



LGP continues European expansion with DEMECAN order


(20min delay)
Last
81.0¢
Change
0.000(0.00%)
Mkt cap ! $188.4M
Open High Low Value Volume
82.0¢ 85.0¢ 81.0¢ $178.1K 214.9K

Buyers (Bids)

No. Vol. Price($)
16 176972 81.0¢
 

Sellers (Offers)

Price($) Vol. No.
85.0¢ 59266 4
View Market Depth
Last trade - 16.10pm 27/07/2021 (20 minute delay) ?
(live)
Last
84.5¢
  Change
0.000 ( 2.96 %)
Open High Low Volume
84.5¢ 85.0¢ 81.0¢ 62931
Last updated 15.59pm 27/07/2021 (live) ?
LGP (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.